Neonatal lipopolysaccharide (LPS) exposure-induced brain inflammation resulted in motor dysfunction and brain dopaminergic neuronal injury, and increased the risks of neurodegenerative disorders in adult rats. Our previous studies showed that intranasal administration of insulin-like growth factor-1 (IGF-1) protects against LPS-induced white matter injury in the developing rat brain. To further examine whether IGF-1 protects against LPS-induced brain neuronal injury and neurobehavioral dysfunction, recombinant human IGF-1 (rhIGF-1) at a dose of 50 µg/pup was administered intranasally 1 h following intracerebral injection of LPS (1 mg/kg) in postnatal day 5 (P5) Sprague-Dawley rat pups. Neurobehavioral tests were carried out from P7 to P21, and brain neuronal injury was examined at P21. Our results showed that LPS exposure resulted in disturbances of motor behaviors in juvenile rats. Moreover, LPS exposure caused injury to central catecholaminergic neurons, as indicated by a reduction of tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra (SN), ventral tegmental area (VTA) and olfactory bulb (OB), and brain noradrenergic neurons, as indicated by a reduction of TH immunoreactivity in the locus coeruleus (LC) of the P21 rat brain. The LPS-induced reduction of TH+ cells was observed at a greater degree in the SN and LC of the P21 rat brain. Intranasal rhIGF-1 treatment attenuated LPS-induced central catecholaminergic neuronal injury and motor behavioral disturbances, including locomotion, beam walking test and gait analysis. Intranasal rhIGF-1 administration also attenuated LPS-induced elevation of IL-1β levels and numbers of activated microglia, and cyclooxygenase-2+ cells, which were double labeled with TH+ cells in the SN, VTA, OB and LC of the P21 rat brain. These results suggest that IGF-1 may provide protection against neonatal LPS exposure-induced central catecholaminergic neuronal injury and motor behavioral disturbances, and that the protective effects are associated with the inhibition of microglia activation and the reduction of neuronal oxidative stress by the suppression of the neuronal cyclooxygenase-2 expression.

Keywords:
Lipopolysaccharide, Neuroinflammation, Locus coeruleus, Insulin-like growth factor-1, Microglia, Cyclooxygenase-2, Substantia nigra, Ventral tegmental area
1.
Raetz CR, Whitfield C: Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:635-700.
2.
Fan LW, Tien LT, Lin RC, Simpson KL, Rhodes PG, Cai Z: Neonatal exposure to lipopolysaccharide enhances vulnerability of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life. Neurobiol Dis 2011;44:304-316.
3.
Ling Z, Zhu Y, Tong C, Snyder JA, Lipton JW, Carvey PM: Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006;199:499-512.
4.
Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC: Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001;21:1302-1312.
5.
Fan LW, Pang Y, Lin S, Tien LT, Ma T, Rhodes PG, Cai Z: Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res 2005;82:71-82.
6.
Fan LW, Tien LT, Mitchell HJ, Rhodes PG, Cai Z: α-Phenyl-n-tert-butyl-nitrone ameliorates hippocampal injury and improves learning and memory in juvenile rats following neonatal exposure to lipopolysaccharide. Eur J Neurosci 2008;27:1475-1484.
7.
Torres-Aleman I: Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol 2010;70:384-396.
8.
Bunn RC, King WD, Winkler MK, Fowlkes JL: Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children. Pediatr Res 2005;58:89-93.
9.
Fernandez AM, Torres-Aleman I: The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012;13:225-239.
10.
Bassil F, Fernagut PO, Bezard E, Meissner WG: Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 2014;118:1-18.
11.
Zemva J, Schubert M: The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. CNS Neurol Disord Drug Targets 2014;13:322-337.
12.
Park SE, Lawson M, Dantzer R, Kelley K, McCusker RH: Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. J Neuroinflamm 2011;8:179.
13.
Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P: IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2684-2690.
14.
Hanson LR, Frey WH 2nd: Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9:S5.
15.
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496.
16.
Cai Z, Fan LW, Lin S, Pang Y, Rhodes PG: Intranasal administration of insulin-like growth factor-1 protects against lipopolysaccharide-induced injury in the developing rat brain. Neuroscience 2011;194:195-207.
17.
Lin S, Fan LW, Rhodes PG, Cai Z: Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009;217:361-370.
18.
Liu XF, Fawcett JR, Hanson LR, Frey WH 2nd: The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 2004;13:16-23.
19.
Wood TL, Loladze V, Altieri S, Gangoli N, Levison SW, Brywe KG, Mallard C, Hagberg H: Delayed IGF-1 administration rescues oligodendrocyte progenitors from glutamate-induced cell death and hypoxic-ischemic brain damage. Dev Neurosci 2007:29:302-310.
20.
Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC: IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Mol Neurobiol 2014;49:1126-1142.
21.
Vig PJ, Subramony SH, D'Souza DR, Wei J, Lopez ME: Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 2006;69:573-579.
22.
Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC: Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells. Free Radic Biol Med 2014;74:129-144.
23.
Bardou I, Kaercher RM, Brothers HM, Hopp SC, Royer S, Wenk GL: Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem. Neurobiol Aging 2014;35:1065-1073.
24.
Hopp SC, Royer SE, D'Angelo HM, Kaercher RM, Fisher DA, Wenk GL: Differential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the substantia nigra and locus coeruleus. J Neuroimmune Pharmacol 2015;10:35-44.
25.
Straley ME, Van Oeffelen W, Theze S, Sullivan AM, O'Mahony SM, Cryan JF, O'Keeffe GW: Distinct alterations in motor and reward seeking behavior are dependent on the gestational age of exposure to LPS-induced maternal immune activation. Brain Behav Immun 2017;63:21-34.
26.
He Q, Li YH, Guo SS, Wang Y, Lin W, Zhang Q, Wang J, Ma CG, Xiao BG: Inhibition of rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model. Eur J Neurosci 2016:43:41-52.
27.
Kirsten TB, Chaves GP, Taricano M, Martins DO, Flório JC, Britto LR, Torrão AS, Palermo-Neto J, Bernardi MM: Prenatal LPS exposure reduces olfactory perception in neonatal and adult rats. Physiol Behav 2011:104:417-422.
28.
Hermans RH, Hunter DE, McGivern RF, Cain CD, Longo LD: Behavioral sequelae in young rats of acute intermittent antenatal hypoxia. Neurotoxicol Teratol 1992;14:119-129.
29.
Antoniou K, Papathanasiou G, Panagis G, Nomikos GG, Hyphantis T, Papadopoulou-Daifoti Z: Individual responses to novelty predict qualitative differences in d-amphetamine-induced open field but not reward-related behaviors in rats. Neuroscience 2004;123:613-623.
30.
Karl T, Pabst R, von Horsten S: Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol 2003;55:69-83.
31.
Westin JE, Janssen ML, Sager TN, Temel Y: Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy. Behav Brain Res 2012;226:519-528.
32.
Pang Y, Lin S, Wright C, Shen J, Carter K, Bhatt A, Fan LW: Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 2016;318:157-165.
33.
Gundersen HJG, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987;147:229-263.
34.
Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
35.
Devos D, Defebvre L, Bordet R: Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam Clin Pharmacol 2010;24:407-421.
36.
Bakos J, Duncko R, Makatsori A, Pirnik Z, Kiss A, Jezova D: Prenatal immune challenge affects growth, behavior, and brain dopamine in offspring. Ann NY Acad Sci 2004;1018:281-287.
37.
Harro J, Pahkla R, Modiri A-R, Harro M, Kask A, Oreland L: Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and beta-adrenoceptor binding in the rat. J Neural Transm 1999;106:619-629.
38.
Stone EA, Lin Y, Sarfraz Y, Quartermain D: The role of the central noradrenergic system in behavioral inhibition. Brain Res Rev 2011;67:193-208.
39.
Dutta D, Ali N, Banerjee E, Singh R, Naskar A, Paidi RK, Mohanakumar KP: Low levels of prohibitin in substantia nigra makes dopaminergic neurons vulnerable in Parkinson's disease. Mol Neurobiol 2017, DOI: 10.1007/s12035-016-0328-y.
40.
Lv Z, Jiang H, Xu H, Song N, Xie J: Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 2011;118:361-369.
41.
Chung CY, Koprich JB, Endo S, Isacson O: An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease. J Neurosci 2007;27:8314-8323.
42.
Surmeier DJ, Schumacker PT: Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2013;288:10736-10741.
43.
Mattson MP: Parkinson's disease: don't mess with calcium. J Clin Invest 2012;122:1195-1198.
44.
Del Tredici K, Braak H: Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 2013;84:774-783.
45.
Szczesny E, Basta-Kaim A, Slusarczyk J, Trojan E, Glombik K, Regulska M, Leskiewicz M, Budziszewska B, Kubera M, Lason W: The impact of prenatal stress on insulin-like growth factor-1 and pro-inflammatory cytokine expression in the brains of adult male rats: the possible role of suppressors of cytokine signaling proteins. J Neuroimmunol 2014;276:37-46.
46.
Perez-Munuzuri A, Couce-Pico ML, Bana-Souto A, Lopez-Suarez O, Iglesias-Deus A, Blanco-Teijeiro J, Fernandez-Lorenzo JR, Fraga-Bermudez JM: Preclinical screening for retinopathy of prematurity risk using IGF1 levels at 3 weeks post-partum. PLoS One 2014;9:e88781.
47.
Priego T, Granado M, Ibanez de Caceres I, Martin AI, Villanua MA, Lopez-Calderon A: Endotoxin at low doses stimulates pituitary GH whereas it decreases IGF-I and IGF-binding protein-3 in rats. J Endocrinol 2003;179:107-117.
48.
Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O: Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005;14:1709-1725.
49.
Pang Y, Zheng B, Campbell L, Fan LW, Cai Z, Rhodes PG: IGF-1 can either protect or deteriorate LPS-induced damage to the developing rat brain. Pediatr Res 2010;67:579-584.
50.
Yan H, Mitschelen M, Bixler GV, Brucklacher RM, Farley JA, Han S, Freeman WM, Sonntag WE: Circulating IGF1 regulates hippocampal IGF1 levels and brain gene expression during adolescence. J Endocrinol 2011;211:27-37.
51.
Trojan E, Głombik K, Slusarczyk J, Budziszewska B, Kubera M, Roman A, Lason, W, Basta-Kaim A: The beneficial impact of antidepressant drugs on prenatal stress-evoked malfunction of the insulin-like growth factor-1 (IGF-1) protein family in the olfactory bulbs of adult rats. Neurotox Res 2016;29:288-298.
52.
Stolp HB, Dziegielewska KM, Ek CJ, Potter AM, Saunders NR: Long-term changes in blood-brain barrier permeability and white matter following prolonged systemic inflammation in early development in the rat. Eur J Neurosci 2005;22:2805-2816.
53.
Kooijman R, Coppens A: Insulin-like growth factor-I stimulates IL-10 production in human T cells. J Leuk Biol 2004;76:862-867.
54.
Law HKW, Tu W, Liu E, Lau YL: Insulin-like growth factor I promotes cord blood T cell maturation through monocytes and inhibits their apoptosis in part through interleukin-6. BMC Immunol 2008;9:74.
55.
Spies M, Nesic O, Barrow RE, Perez-Polo JR, Herndon DN: Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound. Gene Ther 2001;8:1409-1415.
56.
Torres-Aleman I: Insulin-like growth factor-1 and central neurodegenerative diseases. Endocrinol Metab Clin North Am 2012;41:395-408.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.